The estimated Net Worth of Frederick L Glick is at least 3.26 千$ dollars as of 23 March 2020. Frederick Glick owns over 5,000 units of Sonnet BioTherapeutics Inc stock worth over 3,261$ and over the last 6 years Frederick sold SONN stock worth over 0$.
Frederick has made over 3 trades of the Sonnet BioTherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Frederick bought 5,000 units of SONN stock worth 2,550$ on 23 March 2020.
The largest trade Frederick's ever made was buying 11,764 units of Sonnet BioTherapeutics Inc stock on 1 December 2018 worth over 20,705$. On average, Frederick trades about 5,191 units every 119 days since 2018. As of 23 March 2020 Frederick still owns at least 4,000 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Frederick Glick stock trades at the bottom of the page.
Frederick's mailing address filed with the SEC is 7621 LITTLE AVENUE, SUITE 414, , CHARLOTTE, NC, 28226.
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: